Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in prurigo nodularis
2019-003801-90Phase 3Completed
- Sponsor
- Sanofi
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prurigo nodularis (PN) comparing Dupilumab with Placebo (2 arms). Started Dec 2019; status: completed.
02
Drugs
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on 2019-003801-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003801-90.